

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 201 736 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
27.04.2005 Bulletin 2005/17

(51) Int Cl.7: **C11B 1/00, A61K 7/00**(21) Application number: **00938838.0**(86) International application number:  
**PCT/ES2000/000227**(22) Date of filing: **27.06.2000**(87) International publication number:  
**WO 2001/004244 (18.01.2001 Gazette 2001/03)**

(54) **COMPOSITIONS OF INTERNAL LIPID EXTRACT OF WOOL AND USE THEREOF IN THE PREPARATION OF PRODUCTS FOR SKIN CARE AND TREATMENT**

ZUSAMMENSETZUNGEN EINES EXTRAKTES AUS INNEREM FETT AUS WOLLE UND DESSEN VERWENDUNG ZUR HERSTELLUNG VON PRODUKTEN ZUR HAUTPFLEGE UND -BEHANDLUNG

COMPOSITIONS COMPRENANT UN EXTRAIT DE LIPIDES INTERNES DE LA LAINE ET UTILISATION DE CET EXTRAIT DANS LA PREPARATION DE PRODUITS POUR LE TRAITEMENT ET LE SOIN DE LA PEAU

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

• **MARTI GELABERT, Meritxell, Insto. de Investi.  
E-08034 Barcelona (ES)**

(30) Priority: **09.07.1999 ES 9901541**

(74) Representative: **Adams, Harvey Vaughan John  
Mathys & Squire,  
120 Holborn  
London EC1N 2SQ (GB)**

(43) Date of publication of application:  
**02.05.2002 Bulletin 2002/18**

(73) Proprietor: **CONSEJO SUPERIOR DE  
INVESTIGACIONES CIENTIFICAS  
28006 Madrid (ES)**

(56) References cited:  
**WO-A1-98/46558 FR-A1- 2 753 200  
US-A- 3 619 116 US-A- 5 830 481**


(72) Inventors:

- **CODERCH NEGRA, M , Luisa, Insto. de Investi.  
E-08034 Barcelona (ES)**
- **FONOLLOSA ARGEMI, Jorge, Insto. de Investi.  
E-08034 Barcelona (ES)**
- **PERA LOPEZ, Montserrat de, Insto. de Investi.  
E-08034 Barcelona (ES)**
- **MAZA RIBERA, Alfonso de la, Insto. de Invest.  
E-08034 Barcelona (ES)**
- **PARRA JUEZ, José Luis, Insto. de Investi.  
E-08034 Barcelona (ES)**

- **L. CODERCH, A. DE LA MAZA ET AL.:  
'Chromatographic characterization of  
international polar lipids from wool' JACOS vol.  
72, no. 6, 1995, pages 715 - 720, XP000986281**
- **L. CODERCH, A. DE LA MAZA ET AL.:  
'Physicochemical characteristics of liposomes  
formed with international wool lipids' JACOS  
vol. 73, no. 12, 1996, pages 1713 - 1718,  
XP000986282**
- **L. CODERCH, M. DEPERA ET AL.: 'The effect of  
liposomes, on skin barrier structure skin  
pharmacol. appl. skin' PHYSIOL. vol. 12, 1999,  
pages 235 - 246, XP001007438**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 201 736 B1**

**COMPOSITIONS OF INTERNAL LIPID EXTRACT OF WOOL AND USE THEREOF  
IN THE PREPARATION OF PRODUCTS FOR SKIN CARE AND TREATMENT****Patent number:** EP1201736**Publication date:** 2002-05-02**Inventor:** CODERCH NEGRA M LUISA (ES); FONOLLOSA  
ARGEMI JORGE (ES); PERA LOPEZ MONTSERRAT  
DE (ES); MAZA RIBERA ALFONSO DE LA (ES);  
PARRA JUEZ JOSE LUIS (ES); MARTI GELABERT  
MERITXELL (ES)**Applicant:** CONSEJO SUPERIOR INVESTIGACION (ES)**Classification:****- international:** C11B1/00; A61K7/00**- european:** A61K8/14; A61K8/63; A61K8/68; A61K8/92F; A61K8/98;  
A61Q19/00; C11B11/00B**Application number:** EP20000938838 20000627**Priority number(s):** WO2000ES00227 20000627; ES19990001541  
19990709**Also published as:** WO0104244 (A1)  
ES2157807 (A1)  
EP1201736 (B1)**Report a data error here****Abstract of EP1201736**

The use of extracts of internal wool-fibre lipids is described, said extracts having a content in ceramides of at least 15% by weight, in the preparation of pharmaceutical or cosmetic compositions for the treatment and care of the skin. The extracts object of the invention show excellent qualities for a sustained and prolonged improvement of the barrier effect of the skin against external aggressions, as well as a good capacity for keeping the degree of hydration of the skin. Said qualities are even better than those obtained with lipid compositions that contain ceramide III, which imitates the stratum corneum itself of human skin.

---

Data supplied from the esp@cenet database - Worldwide

**Description****Field of the art**

- 5 [0001] The present invention relates to the use of lipid extracts internal to wool, rich in ceramides, in the preparation of pharmaceutical products for the treatment of skin and in cosmetic products for the care of the skin.

**Previous state of the art**

- 10 [0002] The term ceramide is assigned to a series of natural lipid structures, such as those described by Downing D. T. et al in The Journal of Investigative Dermatology 84:410-412 (1985). Said ceramides are fatty amides of sphingosine or phytosphingosine and are usually grouped into six types, as indicated in the aforementioned publication of Downing et al
- [0003] The ceramides localised in the stratum corneum of the skin form a substantial part of the lipid barrier of human skin, a barrier that is responsible for skin protection against aggressions from outside medium and for maintaining the necessary hydration balance for good skin preservation.
- [0004] The use of ceramides is well known, both of natural and synthetic origin, in different products for the treatment and care of the skin. Here, it is mentioned, by way of example only, the description of the US patent US-A-5830481.
- 20 [0005] Some extracts of natural products have been described rich that are in ceramides, and their occasion use in cosmetics. Thus, in patent application FR-A-2753200 an extract of lecithin from soy is described, in patent application WO92/13543 an extract from silk worm larvae is described, and in patent applications FR-A-2739853 and WO-A-98/46558 extracts from morera leaves are described.
- [0006] The need remains, therefore, to find new natural extracts rich in ceramides from accessible and cheap materials, which allow cosmetic and pharmaceutical products to be obtained that show improved properties with respect to care and treatment of the skin, above all in terms of improving the degree of hydration. In addition, given their natural origin, they are better accepted than products of synthetic origin.
- 25 [0007] On the other hand, although the use of lanolin in cosmetic and pharmaceutical products for skincare is well known, it is worthwhile bearing in mind that lanolin is the set of lipids that are found on the surface of the wool fibres, and not inside, because said lipids are secreted by the skin of the sheep and are deposited on the surface of the fibres by means of simple contact. There is no relationship between these and the lipids of internal structures of wool fibres, which, as far as the authors of the present invention are aware, to date, have not been described for use in cosmetic and/or pharmaceutical products for skincare.
- 30 [0008] In the publication L. Coderch et al. *J. Am Oil Chem. Soc.* 72:715-720 (1995) describe the lipids of internal structures of wool fibres, as well as a method of extraction to obtain them, and the same authors, in the publication L. Coderch et al. *J. Am. Oil Chem. Soc.* 73:1713-1718 (1996), describe liposomal structures formed by said lipids and a method for obtaining them.
- 35

**Object of the invention**

- 40 [0009] The object of the present invention is the use of extracts of lipids from the inner parts of wool, with a relatively high content of ceramides, in the preparation pharmaceutical products for the treatment of skin and in cosmetic products for skincare. The pharmaceutical compositions that contain the aforementioned extracts and procedures for the production thereof also form part of said object.

**Description of the invention**

- [0010] The extracts of lipids from the inner parts of wool suitable for the object of the present invention, to which hereinafter will also be referred to as IWL (Internal Wool Lipids), are characterised in that they contain at least 15% by weight, preferably more than 25% by weight, of natural ceramides of wool, along with other lipid components such as cholesterol, fatty acids and other lesser components.
- 50 [0011] Said extracts are obtained from wool fibres from sheep of different breeds and varieties, such as Spanish merino. Australian merino. South African merino, New Zealand merino, etc., after submitting said fibres to a process of surface lipid elimination using well known techniques such as washing with detergents or as is described, for example, in the United States patent US-A-3619116. Thus, the extracts object of the invention are substantially free of lanolin.
- 55 [0012] Once treated to eliminate surface lipids, the wool fibres are submitted to a Soxhlet type extraction with an azeotropic mixture of chloroform and methanol, as described in the publication L. Coderch et al. *J. Am Oil Chem. Soc.* 72:715-720 (1995), or by means of a supercritical extraction with CO<sub>2</sub>, well known to those versed in the art, as will be explained in more detail in the section of examples.

[0013] Either of the aforementioned methods for extraction has the advantage that the physical structure of the wool fibres is not substantially affected, maintaining its characteristics of resistance and elasticity. The extracted wool therefore retains its usefulness for subsequent industrial processing in, for example, the manufacture of textiles.

[0014] The elimination of solvents of the solutions obtained during the process of extraction leads to extracts of internal wool lipids being obtained, suitable for the object of the present invention, which can be used indistinctly in the form of oily solutions in physiologically acceptable lipophilic solvents, or in the form of liposomal structures such as those described in the publication L. Coderch et al. *J. Am. Oil Chem. Soc.* 73:1713-1718 (1996). The liposomal forms are preferred due to their stability, ease of handling and formulation, and because of their excellent skin absorption properties.

[0015] Analysis of the extracts by means of thin layer chromatography (TLC) coupled to flame ionisation detector (FID) system shows a ceramide content of greater than 15% by weight with respect to the total lipids extracted, preferably greater than 25% by weight, and with variable free fatty acid and cholesterol contents, lying, for each one of the two aforementioned components, between approximately 5% by weight and approximately 30% by weight with respect to the total of lipids extracted, in addition to other minority components.

[0016] In general, the technique of supercritical extraction with CO<sub>2</sub> provides extracts with a somewhat greater ceramide content using the Soxhlet extraction technique but, on the other hand, the yield of the extraction is somewhat smaller. Both types of extract are useful for the purposes of the present invention and, as a result, should be considered as lying within the scope thereof.

[0017] The tests of application of the IWLs to human skin, which will be explained in more detail in the section of examples, show that said extracts show a sharp reduction in transepidermal water loss (TEWL) and an improvement in the ability to hydrate the skin, above all in conditions of chemical or mechanical attack, with values clearly more favourable than those obtained with comparative samples of compositions of commercially available ceramides that imitate the nature of the lipids of the stratum corneum.

[0018] Thus, the IWLs object of the present invention can be formulated advantageously in different proportions, as essential components in pharmaceutical and/or cosmetic compositions for the care and treatment of human skin.

[0019] The aforementioned pharmaceutical and/or cosmetic compositions can be any of the types known by one versed in the art for topical application, such as pomades, ointments, creams, emulsions, solutions, tinctures, etc, which may be prepared by association of IWLs with physiologically acceptable excipients and other components of a suitable finish, using techniques well known to those skilled in the art such as mixing, dissolving, the types of composition and additives and auxiliary components described in the US patent US-A-5830481

[0020] The compositions thus obtained show an excellent capacity for reinforcing the protecting lipid barrier of human skin and measurably improve the degree of hydration of said barrier.

[0021] The examples that are given below are for providing an expert in the art with a sufficiently clear and complete explanation of the present invention, but they should not be considered as limitations to the essential aspects of the object thereof, as has been presented in previous sections of this specification.

## Examples

### Example 1:- Prior conditioning of the wool fibres

[0022] The wool is obtained from living sheep by physical shearing and then the surface fats, also called lanolin, are removed by means of an industrial washing, generally in washing sets consisting of 6 troughs, using a mixture of sodium carbonate and non-ionic surfactant oxyethylenate with 8 to 9 moles of ethylene oxide as detergent. Once the wool has been delanolinised, it is submitted to a treatment of combing the fibres and elimination of mechanical impurities and, then, to soaking in distilled water for a short period of time, in order to eliminate part of the dust and other fine particles contained therein. Finally, the wool fibres are dried at room temperature and humidity, finishing the conditioning thereof with a period of 24 hours at 20° C and a RH of 60%.

### Example 2:- Extraction of internal lipids using Soxhlet

[0023] 12 g of conditioned wool obtained from example 1 are weighed and introduced into a Soxhlet fitted with a cellulous cartridge to prevent the passage of any foreign particles still remaining in the wool. The extractor solvent is a mixture chloroform/methanol (79:21) with a bath ratio of 1/30, which implies a solvent volume of 360 mL. The extraction is performed at 72° C for 5 hours, a time period equivalent to six cycles of the Soxhlet. The distillate with the lipid extract is evaporated using a rotavapor apparatus, made up to 10 mL in a solution of chloroform/methanol (2:1) and stored at refrigeration temperature (4° C). Then, 1 mL of solution is evaporated to determine, using a gravimetric method, the amount extracted

[0024] By means of the procedure presented above five varieties of merino wool are extracted which provide the

following extraction yields, in which the percentage is expressed by weight of IWL obtained with respect to the initial weight of the wool fibre extracted:

Spanish	0.947 %
South African	0.916 %
New Zealand	1.037 %
Australian	1.012 %
Russian	1.415 %

[0025] For a quantitative analysis of the IWLs obtained a thin layer chromatography (TLC) technique is used coupled to a flame ionisation detector (FID) in the automatic apparatus Iatroscan® (Latron Lab. Inc. Tokyo, Japan). The lipid extracts are deposited directly (1.6 µL) with an automatic depositor (Sample spotter SES 3202/IS-01, Germany) on silica columns 10 cm long (Silica Gel SIII Chromarods) and are eluted vertically with three mixtures of solvents in order of decreasing polarity: 1) twice with chloroform/methanol/water (57:12:0.6) up to 2.5 cm; 2) Hexane/Diethyl ether/Formic acetate (50:20:0.3) up to 8 cm; and 3) Hexane/Benzene (35:35) up to 10 cm. After each elution, the solvent is removed by heating at 60° C followed by cooling in a chamber at room temperature and dryness. The same procedure is applied to the standards: Palmitic acetate, cholesterol and ceramide III to thus determine their calibration curves and enabling subsequent quantification of each component. The standards are acquired from Sigma Co (St. Louis, M. O.) in analytic grade and stored in chloroform/methanol under refrigeration until the moment in which they are used.

[0026] The results obtained with the five samples of wool extracted are presented in table I, in which said results are expressed as percentages by weight with respect to total weight of IWL extract.

Table I:-

Chemical composition of the IWLs obtained by means of extraction procedure with Soxhlet.				
Variety of merino wool	Free fatty acids (%)	Cholesterol (%)	Ceramides (%)	Rest (*) (%)
Spanish	20.09	21.25	31.88	26.79
South African	22.44	24.74	29.30	23.52
New Zealand	32.57	17.70	27.65	22.08
Australian	23.39	25.28	25.98	25.35
Russian	13.30	12.71	34.89	39.10

(\*) Remaining lipid components not quantified, which are found in lower proportions, such as cholesterol esters, mono-, di- and triglycerides; derivatives of oxidated cholesterol, cerebrosides, cholesterol sulphate, etc.

#### Example 3:- Supercritical extraction of internal lipids using CO<sub>2</sub> (SFE)

[0027] The apparatus used to perform the supercritical extraction has a double syringe pump (SFC-3000; Fisons, Milan, Italy) that distributes the CO<sub>2</sub> (SFE grade 99.998%, Praxir España, Barcelona, Spain) and the modifier of polarity (Methanol in analytical grade, Merck, Darmstadt, Germany), in the desired proportions. The function of the modifier is to increase the capacity of extraction and dissolving of CO<sub>2</sub>. The flow of liquid is adjusted by means of a regulating valve (Hoke Inc, Creskill, NJ, USA) to 1.5-2.0 mL.min<sup>-1</sup>, measured from the LCD of the pump, keeping the temperature at 100° C.

[0028] 4.8 g of wool conditioned in accordance with the procedure of example 1 are introduced into the cylinder where the extraction takes place in supercritical conditions for CO<sub>2</sub>, these being 340 atmospheres. 20 min, at a temperature of 100° C and 10% methanol. The total volume of liquid used for the extraction is 4-5 times the volume of the cell. The extract is collected in a 15-mL vial sealed beforehand with septum (Supelco, Bellefonte PA, USA) which has an outlet to eliminate decompressed CO<sub>2</sub>. The extract is concentrated until dry under nitrogen flow, or by heating to 60° C, in order to eliminate excess solvent. The IWL extracted is quantified using a gravimetric method and resuspended in chloroform/methanol 2:1 (1 mL), keeping under refrigeration.

[0029] Following the extraction procedure described above, two varieties of merino wool are extracted which provide the following extraction yields, in which the percentage is expressed by weight of IWL extract with respect to the initial weight of the wool fibre extracted.

Spanish	0.290 %
New Zealand	0,355 %

[0030] For quantitative analysis of the IWL obtained the chromatographic technique already described in example 2 is used, and the results obtained with the two samples of wool extracted are presented in table II, in which said results are expressed as percentages by weight with respect to total weight of IWL extract.

Table II:-

Chemical composition of the IWLs obtained by means of supercritical extraction with CO <sub>2</sub> (SFE)				
Variety of merino wool	Free fatty acids (%)	Cholesterol (%)	Ceramides (%)	Rest (*) (%)
Spanish	17.75	7.41	45.29	29.55
New Zealand	26.02	7.75	29.73	36.50

(\*) Remaining lipid components not quantified, which are found in lower proportions, such as cholesterol esters, mono-, di- and triglycerides, derivatives of oxidated cholesterol, cerebroside, cholesterol sulphate, etc.

[0031] As can be seen from comparison of the data obtained in examples 2 and 3, the method of extraction using the Soxhlet provides much better extraction yields, but the SFE method has a smaller affinity for the extraction of cholesterol and a somewhat greater yield with respect to the extraction of the ceramides.

#### Example 4:- Mechanical characteristics of the treated wool fibres

[0032] The wool fibres treated in accordance with the procedures described in examples 2 and 3 are conditioned for 48 hours at 20° C and 60 % R.H. A representative stream of the sample is chosen, immobilized, combed, and weighed and then submitted to the mechanical tests of resistance outlined in the IWTO guideline (E)-5-73 (E) appendix B, recognised in the wool textile industrial sector. The test are carried out ten times, always keeping a grip separation of 5 mm and a deformation gradient of 60 %/min (3 mm/min) using an Instron 5500 strength tester coupled to a computer.

[0033] In table III, the results are shown regarding the toughness expressed in cN/tex, in other words, in centiNewtons (cN) per mg mass of fibre for each metre of fibre (tex), and with regard to deformation, expressed in percentage, compared to a control that corresponds to wool fibres that have not been submitted to the extraction treatment.

Table III:-

Mechanical characteristics of the wool fibres treated.			
Merino variety	Treatment	Roughness cN/tex (% coef. of variance)	Deformation % (% coef. of variance)
Spanish	Not treated	8.91 (11.98)	84.32 (3.75)
	Example 2	7.11 (10.52)	119.62 (2.85)
	Example 3	7.89 (26.35)	43.83 (12.58)
South African	Not treated	9.23 (7.00)	126.92 (6.28)
	Example 2	9.63 (9.41)	127.82 (6.74)
Australian	Not treated	10.34 (10.71)	113.52 (16.28)
	Example 2	10.08 (9.68)	136.92 (11.05)
New Zealand	Not treated	13.64 (7.3)	64.49 (5.5)
	Example 2	12.18 (12.4)	82.46 (11.5)
	Example 3	9.47 (13.17)	55.63 (16.91)

[0034] With regard to the toughness parameter, no important change is observed due to treatment of extraction of the IWLs, either by Soxhlet or by SFE, nor is there a clear tendency to increase or decrease the value. With regard to deformation, the treatment by Soxhlet leads to an increase in these values which could be important in some stages of industrial processing of this material, such as those of combing or spinning. This treatment does not negatively affect the properties of the wool fibres, and the textile produced can be used for normal purposes. With regard to the SFE treatment, the deformation values observed are somewhat smaller than those for the untreated samples, although the use of the textile is not invalidated by this.

[0035] As a result, the procedures for extraction of IWLs from wool described in examples 2 and 3 does not significantly modify the mechanical properties of the wool.

Example 5:- Procedure for obtaining the liposomal forms

[0036] An IWL extract dissolved in chloroform/methanol 2:1 (v/v) from either example 2 or 3 is evaporated to dryness under a nitrogen atmosphere, and the film formed on the walls of the recipient is resuspended with a suitable volume of NaCl solution at 0.9% by weight to obtain a suspension of lipid concentration of 10 mg/ml. The formation of multi-lamina liposomes is carried out by sonicating the sample at 65° C, which is a temperature greater than that of phase transition of the implicated lipids, for 15 minutes in a Labsonic® 1510 sonicator (B. Braun, Germany).

[0037] After leaving to stand for 24 hours at room temperature, uni-lamina liposomes of a defined size are obtained by extruding the multi-lamina liposome suspension three times, at 65° C, through filters with a pore size of 800 x 400 x 200 nm (Millipore®, Ireland), providing a suspension of liposomes whose size can be checked to be approximately 200 nm by means of the technique of light scattering, using a Autosizer® photocorrelation lie spectrometer (Malvern, UK).

Example 6:- Effects of IWL extracts on healthy skin, in the short and long term

[0038] The aim of this trial is to evaluate the effect of topical application of liposomes formed from internal wool lipids on the barrier function and hydration of healthy skin, and compare this with the effect produced by the liposomes obtained from a lipid composition that simulates that of the human stratum corneum (SC) itself.

[0039] The evaluation of these properties of the skin is performed using the measures made with the Tewameter® TM 210 apparatus and the Comeometer® CM 825 apparatus, both from Courage & Khazaka (Germany). The Tewameter apparatus measures the transepidermal water loss (TEWL), which is an indicator of the state of the barrier function of the skin. High values of TEWL correspond to a low barrier function, in other words, to a skin less protected against external aggression and with lower capacity to limit the entrance of foreign substances into the body and the release of water to the environment. The Comeometer apparatus bases its measurement on the capacitance of the skin, in arbitrary units. The capacitance is directly related to the amount of water present in the skin and, therefore, the apparatus is effective at determining hydration of the skin.

[0040] The trials were carried out in six volunteers with healthy skin, one man and five women, with ages lying between 24 and 41 years, using the following preparations:

IWL liposomes	This consists of a liposome suspension at 2.5% by weight, obtained in accordance with that described in example 5, using the IWL extract from Spanish merino wool obtained in example 2.
SC liposomes	This consists of a liposome suspension at 2.5% by weight, obtained in accordance with that described in example 5, using a lipid composition that imitates the stratum corneum of human skin itself, prepared beforehand by mixing 40 parts by weight of ceramide III supplied by Cosmoferm (Holland), 25 parts by weight of palmitic acid, 25 parts by weight of cholesterol and 10 parts by weight of cholesterol sulphate.
Placebo	This consists of an aqueous solution of NaCl at 0.9%, similar to that used to prepare the aforementioned liposome suspensions.

[0041] After acclimatising the volunteers for 15 minutes to a room with the conditions held at 20° C and 60% R.H., two square areas of 2 cm are marked out with adhesive cells to one side of the central area of the forearm. To one of these no application will be made (control) and to the other placebo will be applied. Two equal areas are marked out on the other forearm, where IWL liposomes and SC liposomes are applied.

[0042] Baseline measurements are performed of the TEWL and the capacitance, then 10 µl of the corresponding preparation are applied, measuring the parameters once again after two hours. Once 24 hours have passed (day 1), the parameters will be measured once again and 10 µl of preparation applied once more. This procedure is repeated for the following three days (days 2,3 and 4). Finally, after 3 days from the day of the last application (day 7) the parameters are measured once more.

[0043] The results of the trial, double normalised with respect to the baseline value and the values obtained for the control, are shown in table IV.

Table IV:-

Effects of IWL liposomes on healthy skin						
Time	Variation (base 100) of TEWL			Variation (base 100) of TEWL capacitance		
	Placebo	IWL liposomes	SC liposomes	Placebo	IWL liposomes	SC liposomes
2 hour	101.6	90.1	82.3	89.5	93.0	85.1
1 day	103.7	91.6	92.3	95.9	99.9	100.2
2 days	105.3	98.2	101.4	96.3	103.8	97.0
3 days	99.1	95.8	98.3	104.8	107.0	106.2
4 days	104.2	96.3	93.2	103.3	106.4	104.8
7 days	101.9	79.6	85.5	98.2	107.5	100.4

[0044] It is clearly observed that the liposome preparations improve the barrier effect of the skin during the course of time (reduction of TEWL), although the IWL liposome preparation, object of the present invention, appears more effective over long periods of time.

[0045] With regard to hydration of the skin (increase of capacitance), only the preparation of IWL object of the invention produces an increase therein which is maintained for the seven days of the trial.

#### Example 7:- Short-term effects of the IWL extracts on skin attacked chemically

[0046] In the same fashion as in example 6, with the same group of volunteers, the trials are conducted with the variations that are presented below.

[0047] The areas of skin to be tested are immersed for 15 minutes in a 1% solution by weight of sodium laurylsulphate heated to 35° C. After this, the skin is washed with abundant amounts of distilled water and the treated area dried with absorbent paper.

[0048] The preparation of IWL liposomes applied consists of a liposome suspension at 1% by weight, obtained in accordance with that described in example 5, using the IWL extract from New Zealand merino wool obtained in example 2. The SC liposome preparation is the same as that applied in example 6, but diluted to a concentration of 1% by weight.

[0049] The baseline measurement of the TEWL and capacitance parameters is performed before applying the treatment with the surfactant solution, and the measurement which is considered at time 0 is performed after leaving standing for an hour after finishing the aforementioned treatment. Then, 10 µl of preparation corresponding to each marked area of the skin is applied. The aforementioned measurements are made after 30 minutes, 1, 2 and 3 hours.

[0050] In the present case, measurements of the TEWL parameter do not permit conclusions to be drawn, as the measurement at time 0 is practically identical (10.7 g/m<sup>2</sup>/h) to that obtained at baseline (10.8 g/m<sup>2</sup>/h), indicating that the healthy skin has recovered on its own from the degradation of the barrier effect induced in the first instance by the surfactant in less than an hour.

[0051] With regard to the capacitance parameter (hydration), the results obtained are shown in table V, expressed as % variation with respect to the results obtained for the control area with no application, taking into account that the values for each series have been divided by the value obtained at time 0 for said series, with the aim of balancing the initial conditions of the trial.

Table V.

Effects of IWL liposomes on skin attacked chemically			
Time (hours)	Variation in % of capacitance		
	Placebo	IWL Liposomes	SC liposomes
0	0.0	0.0	0.0
0.5	17.8	23.1	17.3
1	15.2	20.6	14.7
2	16.5	20.3	19.6
3	16.1	21.9	15.4



[0052] Although the three preparations improve the hydration of the skin, which indicates that the saline solution itself (placebo) shows beneficial effects, the IWL liposomes show an increase in the hydration of the skin attacked chemically beforehand by the anionic surfactant used that is clearly better than the other two preparations tested.

#### Example 8 Short-term effects of the IWL extracts on mechanically attacked skin

[0053] In the same fashion as in example 6, with the same group of volunteers, trials are performed introducing the variations that are described below.

[0054] The areas of the skin to be tested are submitted to 15 operations of sticking and removal of strips of Scotch Magic® 810 adhesive tape. The technique, known as stripping, allows layers of stratum corneum of skin to be removed.

[0055] Before applying the technique of stripping, the baseline parameters of TEWL and capacitance are determined, and immediately after performing the 15 stripping actions, these parameters are measured for a time 0. Next, the samples are applied as described in example 7.

[0056] The results obtained are shown in table VI, expressed, as in example 7, as % variation with respect to those obtained for the control area with no application, taking into account that the values of each time 0 for each series have been divided in order to balance the conditions of the trial.

Table VI:-

Effects of IWL liposomes on mechanically attacked skin						
Time (hours)	Variation in % of TEWL			Variation in % of capacitance		
	Placebo	IWL liposomes	SC liposomes	Placebo	IWL liposomes	SC liposomes
0	0.0	0.0	0.0	0.0	0.0	0.0
0.5	6.1	-7.8	10.0	-2.5	8.0	7.6
1	5.6	-9.1	7.6	0.8	9.1	5.2
2	7.9	-3.7	8.2	4.4	9.6	7.1
3	5.5	-6.0	17.6	5.7	8.9	6.5

[0057] The preparation of IWL liposomes is the only one of those tested that showed a clear capacity for regeneration of the barrier effect (lower TEWL) in mechanically attacked skin. Of note is that it is much better than the SC liposomes, consisting of a lipid composition similar to that found in the stratum corneum of the skin itself.

[0058] Once again, although the skin hydration (capacitance) is increased by the three preparations tested, the preparation of IWL liposomes leads to a greater improvement in the hydration of the skin than the other two preparations.

#### Claims

1. Use of an internal wool lipid extract that contains at least 15% by weight of ceramides in the manufacture of cosmetic and pharmaceutical compositions for the care and treatment of the skin.
2. Use, according to claim 1, characterised in that the internal wool lipid extract contains at least 25% by weight of ceramides.
3. Use, according to either claim 1 or claim 2, characterised in that the internal wool lipid extract also contains free fatty acids and cholesterol in proportions, mutually independent, lying between 5% by weight and 30% by weight with respect to the total weight of the extract.
4. Use, according to any of claims 1 to 3, characterised in that the internal wool lipid extract is employed in the form of liposomes.
5. Use, according to claim 4, characterised in that said liposomes are found in aqueous suspension of a solution of sodium chloride.
6. A pharmaceutical and/or cosmetic composition characterised in that it comprises an extract of internal wool lipids that contain at least 15% by weight of ceramides.

7. A composition, according to claim 6, **characterised in that** the extract of internal wool lipids contains at least 25% by weight of ceramides.
- 5 8. A composition, according to either claim 6 or 7, **characterised in that** the extracts of internal wool lipids also contain free fatty acids and cholesterol in proportions, mutually independent, lying between 5% by weight and 30% by weight with respect to the total weight of the extract.
- 10 9. A composition, according to any of claims 6 to 8, **characterised in that** the extract of internal wool lipids are in the form of liposomes.
- 10 10. A composition, according to claim 9, **characterised in that** said liposomes are found in an aqueous suspension of a solution of sodium chloride.
- 15 11. A procedure for obtaining to pharmaceutical and/or cosmetic composition of claims 6 to 10, **characterised in that** it consists of associating the ceramide extracts of claims 1 to 5 with physiologically acceptable excipients.
12. An extract of internal wool lipids that contains at least 15% by weight of ceramides, for use in the manufacture of products for the treatment of skin disorders.
- 20 13. An extract, according to claim 12, **characterised in that** it contains at least 25% by weight of ceramides.
14. An extract, according to either of claims 12 or 13, **characterised in that**, in addition, it contains free fatty acids and cholesterol in proportions, mutually independent, of between 5% by weight and 30% by weight with respect to the total weight of the extract.
- 25 15. An extract, according to any of claims 12 to 14, **characterised in that** it is found in the form of liposomes.
16. An extract, according to claim 15, **characterised in that** said liposomes are found in an aqueous suspension of a solution of sodium chloride.
- 30
- 35
- 40
- 45
- 50
- 55

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/ES 00/00227

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC 7 C 11B 1/00 A61K 7/00		
International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 C 11B, A61K, C07C		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
STN, MISTRAL, EPODOC		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	L. CODERCH, A. DE LA MAZA et al. Chromatographic Characterization of International Polar Lipids from wool. JACOS, Vol. 72, no. 6 715-720 (1995)	
Y	L. CODERCH, A. DE LA MAZA et al. Physicochemical Characteristics of Liposomes Formed with International Wool Lipids. JACOS 73, 1713-1718 (1996)	
P,A	L. CODERCH, M. DEPERA et al. The Effect. of Liposomes, on Skin Barrier Structure Skin Pharmacol Appl skin. Physiol 1999 ; 12 ; 235-246	
A	US 3619116 A (NEIL SAVILLE) 9 November 1971 (09.11.71)	
A	FR 2753200 A1 (PIERRE FABRE DERMO COSMETIQUE SOCIETE ANONYME) 13 March 1998 (13.03.98)	
A	WO 9846558 A1 (CABINET CHANET JACQUES) 22 October 1998 (22.10.98)	
A	US 5830481 A (DANIELE CAUWET-MARTIN et al) 3 November 1998 (03.11.98)	
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 23 October 2000 (23.10.00)		Date of mailing of the international search report 8 November 2000 (08.11.00)
Name and mailing address of the S.P.T.O.		Authorized officer  Telephone-No.

**INTERNATIONAL SEARCH REPORT**  
 Information on patent family members

 International application No  
 PCT/ES 00/00227

Patent document Cited in search report	Publication date	Patent family member(s)	Publication date
US 3619116	09.11.1971	NONE	
FR 2753200	13.03.1998	NONE	
WO 9846558	22.10.1998	FR 2739853 AU 2642297	18.04.1997 11.11.1998
US 5830481	03.11.1998	CA 2158622 PL 310714 EP 0704200 FR 2725130 JP 8113511 HU 73034 CN 1129558 FR 9504727 AT 1556 DE 69500457 ES 2109062 KR 181335 RU 2133117 HU 217525 US 6039962	30.09.1996 01.04.1996 03.04.1996 05.04.1996 07.05.1996 28.06.1996 28.08.1996 08.10.1996 15.08.1997 28.08.1997 01.01.1998 20.03.1999 20.07.1999 28.02.2000 21.03.2000